Internal Med Medical News

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Favia G et al. – ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.

Methods

Over 4 year period, total of 102 bisphosphonate-treated patients affected by ONJ identified
24 patients underwent bisphosphonate therapy for non-neoplastic disease and profile analyzed

Results

In study cohort, bisphosphonates administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%)
Duration of therapy until presentation of ONJ ranging from 11 to 40 months
Most common triggering event dentoalveolar surgery
All patients nonsmokers
6 manifested multiple ONJ lesions
3 had possible comorbidities
Surgical debridement performed in 19 patients for total of 22 lesions, which were individually considered in followup
Latter showed complete remission of ONJ in 21/22 lesions